DOCSLIB.ORG

DPAGT1 Antibody (Pab)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
DPAGT1 Antibody (Pab) 21.10.2014DPAGT1 antibody (pAb) Rabbit Anti-Human/Mouse DPAGT1 (DGPT, GPT, ALG7, G1PT, UAGT, UGAT, CDG1J, CDG -Ij) Instruction Manual Catalog Number PK-AB718-6485 Synonyms DPAGT1 Antibody: DPAGT, DGPT, GPT, ALG7, G1PT, UAGT, UGAT, CDG1J, CDG-Ij, UDP-N- acetylglucosamine-dolichyl-phosphate N-acetylglucosaminephosphotransferase Description The UDP-N-acetylglucosamine-dolichyl-phosphate N-acetyl-glucosaminephosphotransferase (DPAGT1) is an enzyme that catalyzes the first step in the dolichol-linked oligosaccharide pathway for glycoprotein biosynthesis. Mutations in this integral endoplasmic reticulum (ER) membrane protein enzyme belongs to the glycosyltransferase family 4 results in the congenital disorder of glycosylation type Ij with symptoms such as severe hypotonia, medically intractable seizures, mental retardation, microcephaly, and exotropia. Recent experiments have shown that DPAGT1 is a target of the Wnt/beta-catenin signaling pathway, with Wnt3a inducing higher DPAGT1 mRNA expression. Quantity 100 µg Source / Host Rabbit Immunogen DPAGT1 antibody was raised against a 17 amino acid synthetic peptide near the amino terminus of human DPAGT1. Purification Method Affinity chromatography purified via peptide column. Clone / IgG Subtype Polyclonal antibody Species Reactivity Human, Mouse Specificity At least four isoforms of DPAGT1 are known to exist; this antibody will recognize the two longest isoforms. DPAGT1 antibody is predicted to not cross-react with UHRF1BP1. Formulation Antibody is supplied in PBS containing 0.02% sodium azide. Reconstitution During shipment, small volumes of antibody will occasionally become entrapped in the seal of the product vial. For products with volumes of 200 μl or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container’s cap. Storage & Stability Antibody can be stored at 4ºC for three months and at -20°C for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. Applications E, WB, IHC, IF |Note: Antibody might be suitable for other applications not tested so far. Optimal concentrations for each application have to be determined indivudually. DPAGT1 antibody can be used for detection of DPAGT1 by Western blot at 1 µg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 µg/mL. For immunofluorescence start at 20 µg/mL. Images Available upon request. References Wu X, Rush JS, Karaoglu D, et al. Deficiency of UDP-GlcNAc:Dolichol Phosphate N- Acetylglucosamine-1 Phosphate Transferase (DPAGT1) causes a novel congenital disorder of glycosylation type Ij. Hum. Mutat. 2003; 22:144-50. Bretthauer RK. Structure, expression, and regulation of UDP-GlcNAc:dolichol phosphate GlcNAc- 1-phosphate transferase (DPAGT1). Curr. Drug Targets 2009; 10:477-82 Sengupta PK, Bouchie MP, and Kukuruzinska MA. N-glycosylation gene DPAGT1 is a target of the Wnt/beta-catenin signaling pathway. J. Biol. Chem. 2010; 285:31164-73. Images Available upon request. Related Products Cat. No. PK-AB718-6485 - DPAGT1 Peptide Cat. No. PK-AB718-1405 - Mouse Kidney Tissue Lysate FOR IN VITRO RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC PROCEDURES. PromoCell GmbH North America 1 – 866 – 251 – 2860 (toll free) Email: [email protected] Sickingenstr. 63/65 Deutschland 0800 – 776 66 23 (gebührenfrei) www.promokine.info 69126 Heidelberg France 0800 90 93 32 (ligne verte) Germany United Kingdom 0800 – 96 03 33 (toll free) Other Countries +49 6221 – 649 34 0 09/2014 .
Load more

Recommended publications
  • Congenital Disorders of Glycosylation from a Neurological Perspective
    brain sciences Review Congenital Disorders of Glycosylation from a Neurological Perspective Justyna Paprocka 1,* , Aleksandra Jezela-Stanek 2 , Anna Tylki-Szyma´nska 3 and Stephanie Grunewald 4 1 Department of Pediatric Neurology, Faculty of Medical Science in Katowice, Medical University of Silesia, 40-752 Katowice, Poland 2 Department of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland; [email protected] 3 Department of Pediatrics, Nutrition and Metabolic Diseases, The Children’s Memorial Health Institute, W 04-730 Warsaw, Poland; [email protected] 4 NIHR Biomedical Research Center (BRC), Metabolic Unit, Great Ormond Street Hospital and Institute of Child Health, University College London, London SE1 9RT, UK; [email protected] * Correspondence: [email protected]; Tel.: +48-606-415-888 Abstract: Most plasma proteins, cell membrane proteins and other proteins are glycoproteins with sugar chains attached to the polypeptide-glycans. Glycosylation is the main element of the post- translational transformation of most human proteins. Since glycosylation processes are necessary for many different biological processes, patients present a diverse spectrum of phenotypes and severity of symptoms. The most frequently observed neurological symptoms in congenital disorders of glycosylation (CDG) are: epilepsy, intellectual disability, myopathies, neuropathies and stroke-like episodes. Epilepsy is seen in many CDG subtypes and particularly present in the case of mutations
    [Show full text]
  • Targeted Polymerase Chain Reaction-Based Enrichment and Next Generation Sequencing for Diagnostic Testing of Congenital Disorders of Glycosylation Melanie A
    ARTICLE Targeted polymerase chain reaction-based enrichment and next generation sequencing for diagnostic testing of congenital disorders of glycosylation Melanie A. Jones, PhD1, Shruti Bhide, MS1, Ephrem Chin, MB(ASCP), QLC1, Bobby G. Ng, BS2, Devin Rhodenizer, BS1, Victor W. Zhang, MD, PhD1, Jessica J. Sun, MS1, Alice Tanner, PhD, MS1, Hudson H. Freeze, PhD2, and Madhuri R. Hegde, PhD, FACMG1 2 Purpose: Congenital disorders of glycosylation are a heterogeneous stability and in the immune response ; hence, the proper devel- group of disorders caused by deficient glycosylation, primarily affecting opment and functioning of many organ systems depend on the N-linked pathway. It is estimated that more than 40% of congenital normal N-glycosylation. Deficient N-glycosylation results in 3 disorders of glycosylation patients lack a confirmatory molecular multiple organ dysfunction that can be life threatening. Con- diagnosis. The purpose of this study was to improve molecular genital disorders of glycosylation (CDG) are a group of more diagnosis for congenital disorders of glycosylation by developing than 30 autosomal recessive disorders caused by deficient gly- 4 and validating a next generation sequencing panel for comprehensive cosylation, primarily affecting the N-linked pathway. Symp- mutation detection in 24 genes known to cause congenital disorders toms of CDG can include severe developmental delay, ataxia, of glycosylation. Methods: Next generation sequencing validation seizures, liver fibrosis, retinopathy, cardiac dysfunction, and 3,5 was performed on 12 positive control congenital disorders of gly- coagulopathies. CDG occurs worldwide, with an estimated 6 cosylation patients. These samples were blinded as to the disease- prevalence as high as 1 in 20,000.
    [Show full text]
  • Impacts of Massively Parallel Sequencing for Genetic Diagnosis of Neuromuscular Disorders
    Acta Neuropathol (2013) 125:173–185 DOI 10.1007/s00401-012-1072-7 REVIEW Impacts of massively parallel sequencing for genetic diagnosis of neuromuscular disorders Nasim Vasli • Jocelyn Laporte Received: 8 October 2012 / Revised: 27 November 2012 / Accepted: 28 November 2012 / Published online: 7 December 2012 Ó Springer-Verlag Berlin Heidelberg 2012 Abstract Neuromuscular disorders (NMD) such as neu- We remind the challenges and benefit of obtaining an ropathy or myopathy are rare and often severe inherited accurate genetic diagnosis, introduce the massively parallel disorders, affecting muscle and/or nerves with neonatal, sequencing technology and its novel applications in diag- childhood or adulthood onset, with considerable burden for nosis of patients, prenatal diagnosis and carrier detection, the patients, their families and public health systems. and discuss the limitations and necessary improvements. Genetic and clinical heterogeneity, unspecific clinical fea- Massively parallel sequencing synergizes with clinical and tures, unidentified genes and the implication of large and/or pathological investigations into an integrated diagnosis several genes requiring complementary methods are the approach. Clinicians and pathologists are crucial in patient main drawbacks in routine molecular diagnosis, leading to selection and interpretation of data, and persons trained in increased turnaround time and delay in the molecular data management and analysis need to be integrated to the validation of the diagnosis. The application of massively diagnosis pipeline. Massively parallel sequencing for parallel sequencing, also called next generation sequenc- mutation identification is expected to greatly improve ing, as a routine diagnostic strategy could lead to a rapid diagnosis, genetic counseling and patient management. screening and fast identification of mutations in rare genetic disorders like NMD.
    [Show full text]
  • Sphingomyelin Suppresses Hedgehog Signaling by Restricting Cholesterol Accessibility at the Ciliary Membrane
    bioRxiv preprint doi: https://doi.org/10.1101/699819; this version posted July 16, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Sphingomyelin suppresses Hedgehog signaling by restricting cholesterol accessibility at the ciliary membrane 1# 1# 1 1 1 Maia Kinnebrew ,​ Ellen J. Iverson ,​ Bhaven B. Patel ,​ Ganesh V. Pusapati ,​ Jennifer H. Kong ,​ Kristen A. 3 ​ 1,5 ​ 4 ​ 2 ​ 3* ​ Johnson ,​ Giovanni Luchetti ,​ Douglas F. Covey ,​ Christian Siebold ,​ Arun Radhakrishnan ​ and Rajat ​ ​ ​ ​ ​ Rohatgi1* ​ 1 Departments​ of Biochemistry and Medicine, Stanford University School of Medicine, Stanford, California, United States of America 2 Division​ of Structural Biology, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK 3 Department​ of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390 4 Department​ of Developmental Biology and Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine, St. Louis, Missouri, United States of America 5 Current​ address: Department of Physiological Chemistry, Genentech, South San Francisco, CA # MK​ and EJI contributed equally to this study. * Correspondence​ to [email protected] or [email protected] bioRxiv preprint doi: https://doi.org/10.1101/699819; this version posted July 16, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
    [Show full text]
  • A Genomic Approach to Delineating the Occurrence of Scoliosis in Arthrogryposis Multiplex Congenita
    G C A T T A C G G C A T genes Article A Genomic Approach to Delineating the Occurrence of Scoliosis in Arthrogryposis Multiplex Congenita Xenia Latypova 1, Stefan Giovanni Creadore 2, Noémi Dahan-Oliel 3,4, Anxhela Gjyshi Gustafson 2, Steven Wei-Hung Hwang 5, Tanya Bedard 6, Kamran Shazand 2, Harold J. P. van Bosse 5 , Philip F. Giampietro 7,* and Klaus Dieterich 8,* 1 Grenoble Institut Neurosciences, Université Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, 38000 Grenoble, France; [email protected] 2 Shriners Hospitals for Children Headquarters, Tampa, FL 33607, USA; [email protected] (S.G.C.); [email protected] (A.G.G.); [email protected] (K.S.) 3 Shriners Hospitals for Children, Montreal, QC H4A 0A9, Canada; [email protected] 4 School of Physical & Occupational Therapy, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3G 2M1, Canada 5 Shriners Hospitals for Children, Philadelphia, PA 19140, USA; [email protected] (S.W.-H.H.); [email protected] (H.J.P.v.B.) 6 Alberta Congenital Anomalies Surveillance System, Alberta Health Services, Edmonton, AB T5J 3E4, Canada; [email protected] 7 Department of Pediatrics, University of Illinois-Chicago, Chicago, IL 60607, USA 8 Institut of Advanced Biosciences, Université Grenoble Alpes, Inserm, U1209, CHU Grenoble Alpes, 38000 Grenoble, France * Correspondence: [email protected] (P.F.G.); [email protected] (K.D.) Citation: Latypova, X.; Creadore, S.G.; Dahan-Oliel, N.; Gustafson, Abstract: Arthrogryposis multiplex congenita (AMC) describes a group of conditions characterized A.G.; Wei-Hung Hwang, S.; Bedard, by the presence of non-progressive congenital contractures in multiple body areas.
    [Show full text]
  • Breadth-First Search Based Approach to Enumerating Chemical Compounds Containing Outerplanar Fused Benzene Ring Substructures
    Breadth-first Search Based Approach to Enumerating Chemical Compounds Containing Outerplanar Fused Benzene Ring Substructures Jina Jindalertudomdee Bioinformatics Center, Institute for Chemical Research, Kyoto University, Japan Structure enumeration is a problem of generating all non-redundant chemical compounds based on a given constraint, such as a chemical formula. It is important in chemoinformatics since it appears as a subproblem of several critical problems, such as drug discovery and structure elucidation. Until now, various algorithms have been proposed to solve the structure-enumeration problem. With the goal of enumerating all possible structures, some tools require impractical computation time for a moderate number of atoms in the input chemical formula. Therefore, alternative tools that can be executed in a reasonable period of time, but have the restriction of the structure of enumerated compounds, were developed. For example, a combination of BfsSimEnum and BfsMulEnum1 can enumerate acyclic compounds efficiently using a tree structure to represent a chemical compound, where nodes and edges are labeled by atom types and bond multiplicities, respectively. This work presents a novel algorithm BfsFusedBenzeneEnum, the extension of BfsSimEnum and BfsMulEnum, for the enumeration of chemical compounds containing no cyclic substructures except for outerplanar fused benzene ring substructures. In BfsFusedBenzeneEnum, a tree structure is used to represent a chemical compound with outerplanar fused benzene ring substructures by defining a special atom type, called b, and a special kind of bond, called a merge bond, to represent a benzene ring and a fused bond between two benzene rings, respectively. A node labeled with an atom type b has an additional attribute called a carbon position list, to keep information about which carbon atoms in the corresponding benzene ring bond with which adjacent nodes.
    [Show full text]
  • 2014 Dpagt1 Alg7 Dean & Gao Handbook
    Metadata of the chapter that will be visualized online Chapter Title Dolichyl-Phosphate (UDP-N-Acetylglucosamine) N- Acetylglucosaminephospho transferase 1 (GlcNAc-1-P Transferase) (DPAGT1) Copyright Year 2014 Copyright Holder Springer Japan Corresponding Author Family Name Dean Particle Given Name Neta Suffix Division/Department Department of Biochemistry and Cell Biology Organization/University Stony Brook University Street Life Sciences Building City Stony Brook State NY Postcode 11794-5215 Country USA Phone 631-632-9309 Email [email protected] Author Family Name Gao Particle Given Name Xiao-Dong Suffix Division/Department The Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Biotechnology Organization/University Jiangnan University Street 1800 Lihu Avenue Postcode 214122 City Wuxi State Jiangsu Province Country China Phone +86-510-85197003 Fax +86-510-85197003 Email [email protected] URL http://klccb.jiangnan.edu.cn/ ketizu1.aspx Abstract In eukaryotes, N-linked protein glycosylation starts with the synthesis of a highly conserved lipid-linked oligosaccharide (LLO) on the endoplasmic reticulum (ER) membrane. As the committed process of N- glycosylation, 14 monosaccharide residues are sequentially transferred onto dolichyl pyrophosphate (dol-P) carrier molecule by a series of glycosyltransferases (GTase) to form the core oligosaccharide precursor Glc3Man9GlcNAc2-P-P-dol. The first half of GTase reactions in LLO synthesis takes place on the cytoplasmic face of ER (Fig. 124.1), which produces Man5GlcNAc2-P-P-dol intermediate from the soluble nucleotide sugar substrates uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) and guanosine diphosphate D-mannose (GDP-man). Once this intermediate is flipped into the lumen of the ER, the next seven sugars are added from dolichol-sugar substrates Man-P-dol and Glc-P- dol to complete the assembly.
    [Show full text]
  • Predicting Immunogenic Tumour Mutations by Combining Mass Spectrometry and Exome Sequencing
    LETTER doi:10.1038/nature14001 Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing Mahesh Yadav1*, Suchit Jhunjhunwala1*, Qui T. Phung1, Patrick Lupardus1, Joshua Tanguay1, Stephanie Bumbaca1, Christian Franci1, Tommy K. Cheung1, Jens Fritsche2, Toni Weinschenk2, Zora Modrusan1, Ira Mellman1, Jennie R. Lill11 &Le´lia Delamarre11 Human tumours typically harbour a remarkable number of somatic identify 4,285 and 949 non-synonymous variants in MC-38 and TRAMP- mutations1. If presented on major histocompatibility complex class C1, respectively (Fig. 1b). To select for high-confidence mutations and I molecules (MHCI), peptides containing these mutations could po- focus on the mutations likely to be expressed in the majority of the tu- tentially be immunogenic as they should be recognized as ‘non-self’ mour cells, we subsequently selected RNA-seq-based variants that were neo-antigens by the adaptive immune system. Recent work has con- present at a minimum of 20% allelic frequency and overlapped with the firmed that mutant peptides can serve as T-cell epitopes2–9.However, exome-based variants. This resulted in 1,290 and 67 expressed mutations few mutant epitopes have been described because their discovery in MC-38 and TRAMP-C1, respectively. Next we identified 170 predicted required the laborious screening of patient tumour-infiltrating lym- neo-epitopes in MC-38 and 6 predicted neo-epitopes in TRAMP-C1 phocytes for their ability to recognize antigen libraries constructed using the NETMHC-3.4 algorithm11 (Fig. 1b, Supplementary Tables 1 following tumour exome sequencing. We sought to simplify the dis- and 2). Despite high density exome reads, only a small number of non- covery of immunogenic mutant peptides by characterizing their gen- synonymous variants and predicted neo-epitopes in TRAMP-C1 were eral properties.
    [Show full text]
  • Blueprint Genetics Congenital Disorders of Glycosylation Panel
    Congenital Disorders of Glycosylation Panel Test code: ME1901 Is a 48 gene panel that includes assessment of non-coding variants. Is ideal for patients with a clinical suspicion of a congenital disorder of N-linked glycosylation or combined defects of glycosylation affecting both the N-linked and O-linked glycosylation pathways. The genes on this panel are included in the Comprehensive Metabolism Panel. About Congenital Disorders of Glycosylation Most subtypes of congenital disorders of glycosylation (CDG) are classified as disorders of N-glycosylation, which involves carbohydrates called N-linked oligosaccharides. These oligosaccharides are created in a specific order to create specific sugar trees, which are then attached to proteins on various cells. Disorders of N-glycosylation are due to an enzyme deficiency or other malfunction somewhere along the N-glycosylation pathway. There are 42 different enzymes in the pathway; any of them may be mutated and cause a disorder belonging to this group. Different mutated enzymes cause different phenotypes. Congenital disorders of N-linked glycosylation are a genetically and phenotypically heterogeneous group of diseases. Most commonly, symptoms begin in early infancy. Manifestations range from mild to severe, involving only protein-losing enteropathy and hypoglycemia or severe intellectual disability with malfunction of several organs. Sometimes the disorder may be fatal. Most patients require nutritional supplements. Most of the individual disorders have been observed only in a very limited number of patients. The most common ones are PMM2-related disorder (approximately 700 patients reported), MPI-related disorder (>20 patients) and ALG6-related disorder (>30 patients). Other types of disorder are extremely rare.
    [Show full text]
  • Glycoconjugate Pathway Connections Revealed by Sequence Similarity Network Analysis of the Monotopic Phosphoglycosyl Transferases
    Glycoconjugate pathway connections revealed by sequence similarity network analysis of the monotopic phosphoglycosyl transferases Katherine H. O’Toolea, Barbara Imperialib,c,1, and Karen N. Allena,1 aDepartment of Chemistry, Boston University, Boston, MA 02215; bDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139; and cDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139 Edited by Stephen J. Benkovic, The Pennsylvania State University, University Park, PA, and approved December 1, 2020 (received for review August 29, 2020) The monotopic phosphoglycosyl transferase (monoPGT) superfam- is transferred to its protein target by an oligosaccharyl transferase ily comprises over 38,000 nonredundant sequences represented in (Fig. 1A) (12, 13) bacterial and archaeal domains of life. Members of the superfamily There are two structurally and mechanistically distinct super- catalyze the first membrane-committed step in en bloc oligosac- families of PGTs, the monotopic PGTs (monoPGTs) and the charide biosynthetic pathways, transferring a phosphosugar from polytopic PGTs (polyPGTs), which catalyze the same transfor- a soluble nucleoside diphosphosugar to a membrane-resident pol- mation. Named for their topology with respect to the membrane, yprenol phosphate. The singularity of the monoPGT fold and its the monoPGTs penetrate a single leaflet of the bilayer whereas employment in the pivotal first membrane-committed step allows the polyPGTs include multiple membrane-spanning helices. confident assignment of both protein and corresponding path- These enzyme superfamilies often co-occur in a single organism, way. The diversity of the family is revealed by the generation allowing for biosynthesis of different glycoconjugate products and analysis of a sequence similarity network for the superfamily, through distinct pathways (1, 2).
    [Show full text]
  • Cholesterol Accessibility at the Ciliary Membrane Controls Hedgehog
    1 Cholesterol accessibility at the ciliary membrane controls 2 Hedgehog signaling 3 4 Maia Kinnebrew1#, Ellen J. Iverson1#, Bhaven B. Patel1, Ganesh V. Pusapati1, Jennifer H. Kong1, 5 Kristen A. Johnson3, Giovanni Luchetti1,5, Kaitlyn M. Eckert6, Jeffrey G McDonald3,6, Douglas F. 6 Covey4, Christian Siebold2, Arun Radhakrishnan3* and Rajat Rohatgi1* 7 8 1Departments of Biochemistry and Medicine, Stanford University School of Medicine, Stanford, 9 California, United States of America 10 2Division of Structural Biology, Wellcome Centre for Human Genetics, University of Oxford, 11 Oxford, UK 12 3Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, 13 TX 75390 14 4Department of Developmental Biology and Taylor Family Institute for Innovative Psychiatric 15 Research, Washington University School of Medicine, St. Louis, Missouri, United States of 16 America 17 5Current address: Department of Physiological Chemistry, Genentech, South San Francisco, CA 18 6Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, TX 19 75390 20 21 #MK and EJI contributed equally to this study. 22 *Correspondence to [email protected] or [email protected] 23 Abstract 24 Previously we proposed that transmission of the Hedgehog signal across the plasma membrane 25 by Smoothened is triggered by its interaction with cholesterol (Luchetti et al., 2016). But how is 26 cholesterol, an abundant lipid, regulated tightly enough to control a signaling system that can 27 cause birth defects and cancer? Using toxin-based sensors that distinguish between distinct 28 pools of cholesterol, we find that Smoothened activation and Hedgehog signaling are driven by 29 a biochemically-defined, small fraction of membrane cholesterol, termed accessible cholesterol.
    [Show full text]
  • Suppression of G6PD Induces the Expression and Bisecting Glcnac
    www.nature.com/bjc ARTICLE Cellular and Molecular Biology Suppression of G6PD induces the expression and bisecting GlcNAc-branched N-glycosylation of E-Cadherin to block epithelial-mesenchymal transition and lymphatic metastasis Yifei Wang1, Qingxiang Li1, Lixuan Niu2,LeXu1, Yuxing Guo1, Lin Wang 1 and Chuanbin Guo1 BACKGROUND: As the rate-limit enzyme of the pentose phosphate pathway, glucose-6-phosphate dehydrogenase (G6PD) plays important roles in tumour progression, but the exact mechanism through which G6PD controls cancer metastasis remains unclear. METHODS: G6PD expression in resected oral squamous cell carcinoma (OSCC) samples was analysed by immunohistochemistry. The effects and mechanism of G6PD suppression on OSCC cell lines were measured by transwell assay, wound healing assay, western and lectin blot, mass spectrometer analysis, ChIP-PCR, and luciferase reporter assay. BALB/c-nude mice were used to establish orthotopic xenograft model. RESULTS: G6PD expression in the tumours of 105 OSCC patients was associated with lymphatic metastasis and prognosis. In vitro cellular study suggested that G6PD suppression impaired cell migration, invasion, and epithelial-mesenchymal transition. Furtherly, G6PD knockdown activated the JNK pathway, which then blocked the AKT/GSK-3β/Snail axis to induce E-Cadherin expression and transcriptionally regulated MGAT3 expression to promote bisecting GlcNAc-branched N-glycosylation of E-Cadherin. An orthotopic xenograft model further confirmed that dehydroepiandrosterone reduced lymphatic metastatic
    [Show full text]